{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:23:45Z","timestamp":1777983825144,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-35021-7","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T19:04:09Z","timestamp":1769627049000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular profiling of primary versus paired asynchronous metastatic clear cell renal cell carcinoma reveals heterogeneity in tumor immune microenvironment"],"prefix":"10.1038","volume":"16","author":[{"given":"Brittney","family":"Cotta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinivas","family":"Nallandhighal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Monda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zayne","family":"Knuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Triner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengyun","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Kasputis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuhong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Udager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saravana M.","family":"Dhanasekaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganesh S.","family":"Palapattu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin P.","family":"Cieslik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd M.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simpa S.","family":"Salami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"issue":"7","key":"35021_CR1","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1002\/cncr.11234","volume":"97","author":"BC Leibovich","year":"2003","unstructured":"Leibovich, B. C. et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97(7), 1663\u20131671. https:\/\/doi.org\/10.1002\/cncr.11234 (2003).","journal-title":"Cancer"},{"issue":"2","key":"35021_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/annonc\/mdl371","volume":"18","author":"TK Choueiri","year":"2007","unstructured":"Choueiri, T. K. et al. Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. Ann. Oncol. 18(2), 249\u2013255. https:\/\/doi.org\/10.1093\/annonc\/mdl371 (2007).","journal-title":"Ann. Oncol."},{"issue":"3","key":"35021_CR3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.eururo.2020.12.005","volume":"79","author":"J Bedke","year":"2021","unstructured":"Bedke, J. et al. Updated European association of urology guidelines on renal cell carcinoma: Nivolumab plus Cabozantinib joins immune checkpoint inhibition combination therapies for treatment-na\u00efve metastatic clear-cell renal cell carcinoma. Eur Urol. 79(3), 339\u2013342. https:\/\/doi.org\/10.1016\/j.eururo.2020.12.005 (2021).","journal-title":"Eur Urol."},{"key":"35021_CR4","doi-asserted-by":"publisher","first-page":"166 175","DOI":"10.1016\/j.eururo.2023.04.003","volume":"84","author":"BH Cotta","year":"2023","unstructured":"Cotta, B. H. et al. Current landscape of genomic biomarkers in clear cell renal cell carcinoma. Eur Urol. 84, 166 175. https:\/\/doi.org\/10.1016\/j.eururo.2023.04.003 (2023).","journal-title":"Eur Urol."},{"key":"35021_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.euros.2021.11.003","volume":"35","author":"A Meerveld-Eggink","year":"2022","unstructured":"Meerveld-Eggink, A. et al. Primary renal tumour response in patients treated with Nivolumab and Ipilimumab for metastatic renal cell carcinoma: real-world data assessment. Eur Urol Open Sci. 35, 54\u201358. https:\/\/doi.org\/10.1016\/j.euros.2021.11.003 (2022).","journal-title":"Eur Urol Open Sci."},{"issue":"12","key":"35021_CR6","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.urolonc.2019.08.012","volume":"37","author":"N Singla","year":"2019","unstructured":"Singla, N. et al. Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma. Urol Oncol. 37(12), 924\u2013931. https:\/\/doi.org\/10.1016\/j.urolonc.2019.08.012 (2019).","journal-title":"Urol Oncol."},{"issue":"2","key":"35021_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.eururo.2022.10.004","volume":"83","author":"Z Bakouny","year":"2023","unstructured":"Bakouny, Z. et al. Upfront cytoreductive nephrectomy for metastatic renal cell carcinoma treated with immune checkpoint inhibitors or targeted therapy: an observational study from the international metastatic renal cell carcinoma database consortium. Eur Urol. 83(2), 145\u2013151. https:\/\/doi.org\/10.1016\/j.eururo.2022.10.004 (2023).","journal-title":"Eur Urol."},{"issue":"3","key":"35021_CR8","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.cell.2018.03.057","volume":"173","author":"S Turajlic","year":"2018","unstructured":"Turajlic, S. et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal. Cell 173(3), 581-594.e12. https:\/\/doi.org\/10.1016\/j.cell.2018.03.057 (2018).","journal-title":"Cell"},{"issue":"3","key":"35021_CR9","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.cell.2018.03.043","volume":"173","author":"S Turajlic","year":"2018","unstructured":"Turajlic, S. et al. Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal. Cell 173(3), 595-610.e11. https:\/\/doi.org\/10.1016\/j.cell.2018.03.043 (2018).","journal-title":"Cell"},{"issue":"21","key":"35021_CR10","doi-asserted-by":"publisher","first-page":"e123468","DOI":"10.1172\/jci.insight.123468","volume":"3","author":"SS Salami","year":"2018","unstructured":"Salami, S. S. et al. Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight. 3(21), e123468. https:\/\/doi.org\/10.1172\/jci.insight.123468 (2018).","journal-title":"JCI Insight."},{"issue":"4","key":"35021_CR11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.neo.2015.03.004","volume":"17","author":"DH Hovelson","year":"2015","unstructured":"Hovelson, D. H. et al. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Neoplasia 17(4), 385\u2013399. https:\/\/doi.org\/10.1016\/j.neo.2015.03.004 (2015).","journal-title":"Neoplasia"},{"issue":"9","key":"35021_CR12","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1101\/gr.189621.115","volume":"25","author":"M Cieslik","year":"2015","unstructured":"Cieslik, M. et al. The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing. Genome Res. 25(9), 1372\u20131381. https:\/\/doi.org\/10.1101\/gr.189621.115 (2015).","journal-title":"Genome Res."},{"issue":"1","key":"35021_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26(1), 139\u2013140. https:\/\/doi.org\/10.1093\/bioinformatics\/btp616 (2010).","journal-title":"Bioinformatics"},{"issue":"7","key":"35021_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43(7), e47. https:\/\/doi.org\/10.1093\/nar\/gkv007 (2015).","journal-title":"Nucleic Acids Res."},{"issue":"43","key":"35021_CR15","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. 102(43), 15545\u201315550. https:\/\/doi.org\/10.1073\/pnas.0506580102 (2005).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"35021_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14, 7. https:\/\/doi.org\/10.1186\/1471-2105-14-7 (2013).","journal-title":"BMC Bioinformatics"},{"key":"35021_CR17","doi-asserted-by":"publisher","DOI":"10.1101\/060012","author":"G Korotkevich","year":"2019","unstructured":"Korotkevich, G., Sukhov, V. & Sergushichev, A. Fast gene set enrichment analysis.. bioRxiv https:\/\/doi.org\/10.1101\/060012 (2019).","journal-title":"bioRxiv"},{"key":"35021_CR18","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The molecular signatures database hallmark gene set collection. Cells Syst. 1, 417\u2013425. https:\/\/doi.org\/10.1016\/j.cels.2015.12.004 (2015).","journal-title":"Cells Syst."},{"issue":"5","key":"35021_CR19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 12(5), 453\u2013457. https:\/\/doi.org\/10.1038\/nmeth.3337 (2015).","journal-title":"Nat Methods."},{"issue":"1","key":"35021_CR20","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 4(1), 2612. https:\/\/doi.org\/10.1038\/ncomms3612 (2013).","journal-title":"Nat Commun."},{"issue":"6","key":"35021_CR21","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","volume":"38","author":"RJ Motzer","year":"2020","unstructured":"Motzer, R. J. et al. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade. Cancer Cell 38(6), 803-817.e4. https:\/\/doi.org\/10.1016\/j.ccell.2020.10.011 (2020).","journal-title":"Cancer Cell"},{"issue":"5","key":"35021_CR22","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.ccell.2024.03.002","volume":"42","author":"RM Saliby","year":"2024","unstructured":"Saliby, R. M. et al. Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes. Cancer Cell 42(5), 732\u2013735. https:\/\/doi.org\/10.1016\/j.ccell.2024.03.002 (2024).","journal-title":"Cancer Cell"},{"key":"35021_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling Survival Data: Extending the Cox Model","author":"TM Therneau","year":"2000","unstructured":"Therneau, T. M. & Grambsch, P. M. The Cox Model. In Modeling Survival Data: Extending the Cox Model (Springer, 2000). https:\/\/doi.org\/10.1007\/978-1-4757-3294-8."},{"issue":"1","key":"35021_CR24","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41467-017-00488-6","volume":"8","author":"MF Gutknecht","year":"2017","unstructured":"Gutknecht, M. F. et al. Identification of the S100 fused-type protein hornerin as a regulator of tumor vascularity. Nat Commun. 8(1), 552. https:\/\/doi.org\/10.1038\/s41467-017-00488-6 (2017).","journal-title":"Nat Commun."},{"issue":"8","key":"35021_CR25","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/ng.2699","volume":"45","author":"Y Sato","year":"2013","unstructured":"Sato, Y. et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 45(8), 860\u2013867. https:\/\/doi.org\/10.1038\/ng.2699 (2013).","journal-title":"Nat Genet."},{"issue":"4","key":"35021_CR26","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.cell.2019.10.007","volume":"179","author":"DJ Clark","year":"2019","unstructured":"Clark, D. J. et al. Integrated proteogenomic characterization of clear cell renal cell carcinoma. Cell 179(4), 964-983.e31. https:\/\/doi.org\/10.1016\/j.cell.2019.10.007 (2019).","journal-title":"Cell"},{"key":"35021_CR27","unstructured":"The Cancer Genome Atlas Program (TCGA) - NCI. May 13, 2022. Accessed May 31, 2023. https:\/\/www.cancer.gov\/ccg\/research\/genome-sequencing\/tcga"},{"issue":"31","key":"35021_CR28","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.1038\/s41388-021-01921-3","volume":"40","author":"A Kaida","year":"2021","unstructured":"Kaida, A. et al. DNAJA1 promotes cancer metastasis through interaction with mutant p53. Oncogene 40(31), 5013\u20135025. https:\/\/doi.org\/10.1038\/s41388-021-01921-3 (2021).","journal-title":"Oncogene"},{"issue":"2","key":"35021_CR29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.canlet.2016.03.046","volume":"376","author":"M Cordani","year":"2016","unstructured":"Cordani, M. et al. Mutant p53 proteins alter cancer cell secretome and tumour microenvironment: Involvement in cancer invasion and metastasis. Cancer Lett. 376(2), 303\u2013309. https:\/\/doi.org\/10.1016\/j.canlet.2016.03.046 (2016).","journal-title":"Cancer Lett."},{"issue":"1","key":"35021_CR30","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1186\/s12885-018-4719-5","volume":"18","author":"SJ Fu","year":"2018","unstructured":"Fu, S. J. et al. Hornerin promotes tumor progression and is associated with poor prognosis in hepatocellular carcinoma. BMC Cancer 18(1), 815. https:\/\/doi.org\/10.1186\/s12885-018-4719-5 (2018).","journal-title":"BMC Cancer"},{"issue":"4","key":"35021_CR31","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nri1806","volume":"6","author":"W Zou","year":"2006","unstructured":"Zou, W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 6(4), 295\u2013307. https:\/\/doi.org\/10.1038\/nri1806 (2006).","journal-title":"Nat Rev Immunol."},{"issue":"9","key":"35021_CR32","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 10(9), 942\u2013949. https:\/\/doi.org\/10.1038\/nm1093 (2004).","journal-title":"Nat Med."},{"issue":"2","key":"35021_CR33","doi-asserted-by":"publisher","first-page":"415","DOI":"10.4049\/jimmunol.1701188","volume":"200","author":"JL Chao","year":"2018","unstructured":"Chao, J. L. & Savage, P. A. Unlocking the complexities of tumor-associated regulatory T cells. J Immunol. 200(2), 415\u2013421. https:\/\/doi.org\/10.4049\/jimmunol.1701188 (2018).","journal-title":"J Immunol."},{"issue":"5","key":"35021_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41389-021-00329-8","volume":"10","author":"M Fernando","year":"2021","unstructured":"Fernando, M. et al. Dysregulated G2 phase checkpoint recovery pathway reduces DNA repair efficiency and increases chromosomal instability in a wide range of tumours. Oncogenesis. 10(5), 1\u201311. https:\/\/doi.org\/10.1038\/s41389-021-00329-8 (2021).","journal-title":"Oncogenesis."},{"issue":"7","key":"35021_CR35","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.3390\/cells9071643","volume":"9","author":"M Oshi","year":"2020","unstructured":"Oshi, M. et al. The E2F pathway score as a predictive biomarker of response to neoadjuvant therapy in ER+\/HER2\u2212 breast cancer. Cells 9(7), 1643. https:\/\/doi.org\/10.3390\/cells9071643 (2020).","journal-title":"Cells"},{"issue":"1","key":"35021_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000491","volume":"8","author":"S Garc\u00eda-Mulero","year":"2020","unstructured":"Garc\u00eda-Mulero, S. et al. Lung metastases share common immune features regardless of primary tumor origin. J Immunother Cancer. 8(1), e000491. https:\/\/doi.org\/10.1136\/jitc-2019-000491 (2020).","journal-title":"J Immunother Cancer."},{"issue":"12","key":"35021_CR37","doi-asserted-by":"publisher","first-page":"6832","DOI":"10.3390\/ijms23126832","volume":"23","author":"A Del Conte","year":"2022","unstructured":"Del Conte, A. et al. Bone metastasis and immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): microenvironment and possible clinical implications. Int J Mol Sci. 23(12), 6832. https:\/\/doi.org\/10.3390\/ijms23126832 (2022).","journal-title":"Int J Mol Sci."},{"key":"35021_CR38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ejca.2018.10.023","volume":"107","author":"F Ruatta","year":"2019","unstructured":"Ruatta, F. et al. Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre. Eur J Cancer. 107, 79\u201385. https:\/\/doi.org\/10.1016\/j.ejca.2018.10.023 (2019).","journal-title":"Eur J Cancer."},{"issue":"3","key":"35021_CR39","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.21873\/anticanres.14913","volume":"41","author":"T Negishi","year":"2021","unstructured":"Negishi, T. et al. Site-specific response to nivolumab in renal cell carcinoma. Anticancer Res. 41(3), 1539\u20131545. https:\/\/doi.org\/10.21873\/anticanres.14913 (2021).","journal-title":"Anticancer Res."},{"key":"35021_CR40","unstructured":"HHLA2 HHLA2 member of B7 family [Homo sapiens (human)] - Gene - NCBI. Accessed August 16, 2024. https:\/\/www.ncbi.nlm.nih.gov\/gene\/11148"},{"key":"35021_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103987","author":"H Ying","year":"2022","unstructured":"Ying, H., Xu, J., Zhang, X., Liang, T. & Bai, X. Human endogenous retrovirus-H long terminal repeat-associating 2: The next immune checkpoint for antitumour therapy. EBioMedicine. https:\/\/doi.org\/10.1016\/j.ebiom.2022.103987 (2022).","journal-title":"EBioMedicine."},{"issue":"1","key":"35021_CR42","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s13059-016-1092-z","volume":"17","author":"Y \u015eenbabao\u011flu","year":"2016","unstructured":"\u015eenbabao\u011flu, Y. et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol. 17(1), 231. https:\/\/doi.org\/10.1186\/s13059-016-1092-z (2016).","journal-title":"Genome Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-35021-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-35021-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-35021-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T10:51:27Z","timestamp":1770634287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-35021-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["35021"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-35021-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7087297\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5473"}}